COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #93 of 231
7/21 Late treatment study
Bernaola et al., medRxiv, doi:10.1101/2020.07.17.20155960 (Preprint)
Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Source   PDF   Share   Tweet
HCQ HR 0.83 [0.77-0.89] based on propensity score matched retrospective analysis of 1,645 hospitalized patients. Prednisone HR 0.85 [0.82-0.88], 14 other medications showed either no signicant benefit or a negative effect.

Bernaola et al., 7/21/2020, retrospective, Spain, Europe, preprint, 7 authors.
risk of death, 17.0% lower, RR 0.83, p < 0.001, treatment 236 of 1498 (15.8%), control 28 of 147 (19.0%).
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit